90 results
Page 3 of 5
S-3ASR
nv7p6kh
10 Aug 20
Automatic shelf registration
5:01pm
424B5
40i85hufavft1s59n9fa
2 Jun 20
Prospectus supplement for primary offering
5:05pm
424B5
c8md3
1 Jun 20
Prospectus supplement for primary offering
6:06am
8-K
EX-10.1
uhcayly4woh1
18 Feb 20
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
8:07am
424B5
ovbi6ckay6o0j
22 Jan 20
Prospectus supplement for primary offering
5:31pm
424B5
p203vo
21 Jan 20
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
ne700p1 szzl3oziw
6 Nov 19
Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update
7:35am
8-K
EX-99.1
x5f2rn9m0vv 87jdabo3
1 Aug 19
Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
7:23am
8-K
EX-99.1
grxwc
18 Jul 19
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE-A4 to Enhance Antitumor Responses
8:11am
8-K
EX-10.4
dtd 1a1jttk
27 Jun 19
Departure of Directors or Certain Officers
8:08am